Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th
Belite Bio announced that Chief Medical Officer Dr. Hendrick Scholl will present at the Deutsche Bank ADR Virtual Investor Conference on April 28. The company highlighted the recent initiation of a rolling NDA submission for tinlarebant in Stargardt disease, following Phase 3 data showing a 35.7% reduction in lesion growth.
Key figures
- Drug Name
- tinlarebant
- Phase Of Trial
- Phase 3
- Lesion reduction
- 35.7%
- Offering proceeds
- $402 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.